A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: The SAFE-ICU study

Roberts, JA; Sime, F; Lipman, J; Hernandez-Mitre, MP; Baptista, JP; Bruggemann, RJ; Darvall, J; De Waele, JJ; Dimopoulos, G; Lefrant, JY; Mat Nor, MB; Rello, J; Seoane, L; Slavin, MA; Valkonen, M; Venditti, M; Wong, WT; Zeitlinger, M; Roger, C

Author(s): Roberts, JA; Sime, F; Lipman, J; Hernandez-Mitre, MP; Baptista, JP; Bruggemann, RJ; Darvall, J; De Waele, JJ; Dimopoulos, G; Lefrant, JY; Mat Nor, MB; Rello, J; Seoane, L; Slavin, MA; Valkonen, M; Venditti, M; Wong, WT; Zeitlinger, M; Roger, C;
Details: Publication Year 2023,Volume 25,Issue #1,Page 1-5
Journal Title: Critical Care and Resuscitation
Publication Type: Protocol
Abstract: OBJECTIVE: To describe whether contemporary dosing of antifungal drugs achieves therapeutic exposures in critically ill patients that are associated with optimal outcomes. Adequate antifungal therapy is a key determinant of survival of critically ill patients with fungal infections. Critical illness can alter an antifungal agents' pharmacokinetics, increasing the risk of inappropriate antifungal exposure that may lead to treatment failure and/or toxicity. DESIGN SETTING AND PARTICIPANTS: This international, multicentre, observational pharmacokinetic study will comprise adult critically ill patients prescribed antifungal agents including fluconazole, voriconazole, posaconazole, isavuconazole, caspofungin, micafungin, anidulafungin, and amphotericin B for the treatment or prophylaxis of invasive fungal disease. A minimum of 12 patients are targeted for enrolment for each antifungal agent, across 12 countries and 30 intensive care units to perform descriptive pharmacokinetics. Pharmacokinetic sampling will occur during two dosing intervals (occasions): firstly, between days 1 and 3, and secondly, between days 4 and 7 of the antifungal course, collecting three samples per occasion. Patients' demographic and clinical data will be collected. MAIN OUTCOME MEASURES: The primary endpoint of the study is attainment of pharmacokinetic/pharmacodynamic target exposures that are associated with optimal efficacy. Thirty-day mortality will also be measured. RESULTS AND CONCLUSIONS: This study will describe whether contemporary antifungal drug dosing achieves drug exposures associated with optimal outcomes. Data will also be used for the development of antifungal dosing algorithms for critically ill patients. Optimised drug dosing should be considered a priority for improving clinical outcomes for critically ill patients with fungal infections.
Department(s): Infectious Diseases
PubMed ID: 37876989
Publisher's Version: https://doi.org/10.1016/j.ccrj.2023.04.002
Open Access at Publisher's Site: https://doi.org/10.1016/j.ccrj.2023.04.002
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-08-20 06:17:51

Last Modified: 2024-08-20 06:56:39